Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
Top Cited Papers
- 7 September 2021
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (10) , 1255-1265
Abstract
Patients with rheumatic diseases are at increased risk of infectious complications; vaccinations are a critical component of their care. Disease-modifying antirheumatic drugs may reduce the immunogenicity of common vaccines. We will review here available data regarding the effect of these medications on influenza, pneumococcal, herpes zoster, SARS-CoV-2, hepatitis B, human papilloma virus and yellow fever vaccines. Rituximab has the most substantial impact on vaccine immunogenicity, which is most profound when vaccinations are given at shorter intervals after rituximab dosing. Methotrexate has less substantial effect but appears to adversely impact most vaccine immunogenicity. Abatacept likely decrease vaccine immunogenicity, although these studies are limited by the lack of adequate control groups. Janus kinase and tumour necrosis factor inhibitors decrease absolute antibody titres for many vaccines, but do not seem to significantly impact the proportions of patients achieving seroprotection. Other biologics (interleukin-6R (IL-6R), IL-12/IL-23 and IL-17 inhibitors) have little observed impact on vaccine immunogenicity. Data regarding the effect of these medications on the SARS-CoV-2 vaccine immunogenicity are just now emerging, and early glimpses appear similar to our experience with other vaccines. In this review, we summarise the most recent data regarding vaccine response and efficacy in this setting, particularly in light of current vaccination recommendations for immunocompromised patients.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (1P30AR072583)
- National Center for Advancing Translational Sciences (KL2TR002370)
- Bristol-Myers Squibb Canada (na)
- School of Medicine, Oregon Health and Science University (Wheels Up Award)
- Pfizer (na)
This publication has 141 references indexed in Scilit:
- Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adultsVaccine, 2013
- The effect of rituximab on vaccine responses in patients with immune thrombocytopeniaBlood, 2013
- Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center StudyClinical and Vaccine Immunology, 2012
- The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational studyArthritis Research & Therapy, 2011
- The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximabVaccine, 2011
- Epidemiology and prevention of hepatitis B virus infectionThe Korean Journal of Hepatology, 2011
- Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatmentArthritis Research & Therapy, 2010
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximabArthritis & Rheumatism, 2009
- Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjectsArthritis Research & Therapy, 2007
- The mortality of rheumatoid arthritisArthritis & Rheumatism, 1994